Lantern Pharma (LTRN) Long-Term Debt Issuances (2020)

Lantern Pharma's (LTRN) quarterly Long-Term Debt Issuances came in at $156096.0 in Q2 2020, up 1105.1% on a QoQ basis from $12953.0 in Q1 2020.

Lantern Pharma (LTRN) Long-Term Debt Issuances (2020) Analysis & Trends

Lantern Pharma (LTRN) has 1 years of Long-Term Debt Issuances data on file, last reported at $156096.0 in Q2 2020.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $156096.0 in Q2 2020, while the trailing twelve-month figure through Dec 2020 was $169049.0 (changed N/A YoY) and the FY2020 annual result came in at $169049.0, changed N/A from the prior year.
Long-Term Debt Issuances improved to $156096.0 in Q2 2020, from $12953.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $156096.0 in Q2 2020 to a low of $12953.0 in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Lantern Pharma	26.05 Mn	26.05 Mn	-	-

Download Data